7 unchanged sentences
333-254534), filed with the SEC on March 19, 2021).
−Removed: Employment Agreement by and between the Registrant and Ashley F.
−Removed: Hall, J.D., dated October 11, 2021.
−Removed: Reneo Pharmaceuticals, Inc.
−Removed: Severance Benefit Plan, as amended, and form of Participation Agreement thereunder.
+Added: Letter Agreement by and between Registrant and Paul W.
+Added: Hoelscher, dated January 20, 2022 (incorporated by reference to Exhibit 10.13 to the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 23, 2022).
+Added: Transition, Separation and Consulting Agreement by and between the Registrant and Vineet R.
+Added: Jindal, dated February 2, 2022 (incorporated by reference to Exhibit 10.14 to the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 23, 2022).
Reneo Pharmaceuticals, Inc.
−Removed: UK Sharesave Sub-Plan to the Reneo Pharmaceuticals, Inc.
−Removed: 2021 Employee Stock Purchase Plan.
−Removed: Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise for Inducement Grant Outside of the Reneo Pharmaceuticals, Inc.
−Removed: 2021 Equity Incentive Plan.
−Removed: Forms of RSU Award Grant Notice and Award Agreement (RSU Award) for Inducement Grant Outside of the Reneo Pharmaceuticals, Inc.
−Removed: 2021 Equity Incentive Plan.
−Removed: Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Chief Executive Officer Pursuant to 18 U.S.C.
+Added: Non-Employee Director Compensation Policy, as amended (incorporated by reference to Exhibit 10.11 to the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 23, 2022).
+Added: Sales Agreement, dated May 2, 2022, by and between the Registrant and SVB Securities LLC (incorporated by reference to Exhibit 1.2 to the Registrant’s Registration Statement on Form S-3 (File No.
+Added: 333-264616), filed with the SEC on May 2, 2022).
+Added: Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .
+Added: Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .
+Added: Certification of Principal Executive Officer Pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 .
−Removed: Certification of Chief Financial Officer Pursuant to 18 U.S.C.
+Added: Certification of Principal Financial Officer Pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 .
10 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: November 12, 2021
RENEO PHARMACEUTICALS, INC.
2 unchanged sentences
(Principal Executive Officer)
−Removed: /s/ Vineet R.
−Removed: Chief Financial Officer
+Added: /s/ Jennifer P.
+Added: Vice President of Finance and Administration
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.